Status:
COMPLETED
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
Lead Sponsor:
Ebima Clifford Okundaye
Conditions:
Chronic Kidney Disease Stages 3-5
Diabetic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes int...
Eligibility Criteria
Inclusion
- Patient with Chronic kidney disease stage 3-5
- Estimated Glomerular function by MDRD of less than 60mls/min
- Patients with declining renal function ( as measured by eGFR by MDRD )
- Rate of decline of eGFR over the last one year of less than 20%
- Negative Serology markers for CKD etiology
- Provider perceived adherence to study follow- up
Exclusion
- Rapid rate of decline in kidney function of \> 10 % over 3 months
- Symptomatic renal failure
- Presence of any suspected Acute renal failure superimposed
- Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
- No known reversible cause of renal decline
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2024
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT06948292
Start Date
March 1 2023
End Date
October 30 2024
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neukidney Inc
Pasedena, Texas, United States, 77504